Illumina explores options for Grail, hires advisers

The company, facing pressure from regulators to divest Grail, also formed a special committee to speed decisions on the fate of the liquid biopsy test maker.

By Susan Kelly • Nov. 10, 2023

Acutus laying off 65% of employees to focus solely on Medtronic heart device deal

The company has decided to exit the mapping and ablation business and focus its remaining cash on the Medtronic partnership.

By Nick Paul Taylor • Nov. 10, 2023

4 takeaways from Stryker’s investor day

The company’s expected return to pre-pandemic operating margins, procedure backlogs and weight loss drugs were among the topics discussed at Wednesday’s event.

By Elise Reuter • Nov. 9, 2023

BD’s 2024 forecast comes in ‘well below’ Wall Street’s expectations

Wall Street analysts called out BD’s disappointing 2024 EPS forecast in notes to investors, following a Thursday morning earnings call.

By Ricky Zipp • Nov. 9, 2023

Masimo lowers outlook, citing constrained hospital budgets

The patient monitoring company is also facing a slowdown in demand for the consumer audio products it acquired in a deal last year.

By Susan Kelly • Nov. 8, 2023

Siemens Healthineers’ Varian rebounds; execs mum on diagnostics sale rumors

The company's diagnostics unit continued to struggle amid layoffs and reports of a potential sale.

By Nick Paul Taylor • Nov. 8, 2023

Zimmer Biomet’s Ivan Tornos sets priorities for first year as CEO

Tornos, who took the helm in August, said the company will grow through internal innovation and M&A.

By Elise Reuter • Nov. 7, 2023

Diabetes tech firms focusing on Type 2 patients

Leaders from Abbott, Dexcom, Tandem and Insulet expect Type 2 uptake of their insulin pumps and CGMs to accelerate as coverage improves and new devices reach the market.

By Elise Reuter • Nov. 7, 2023

5 companies to watch as medtech earnings wind down

Zimmer Biomet, BD, Masimo, Illumina and Medtronic are all set to report financial results as the medtech earnings season draws to a close.

By Nick Paul Taylor • Nov. 6, 2023

Stryker in ‘sprint back to 2019’ as procedures grow and supply chain, staffing pressures improve

The company expects a procedure backlog to boost orthopedic surgery demand in the fourth quarter and through 2024.

By Ricky Zipp • Nov. 3, 2023

Baxter completes biopharma solutions sale, business unit revamp

The company plans to use most of the $3.7 billion in after-tax proceeds from the biopharma solutions sale to repay debt.

By Susan Kelly • Nov. 2, 2023

Drilling down on obesity drugs: What medtech executives are saying

Investor concerns that interest in GLP-1s will slow demand for medical devices and procedures have shaved roughly $370 billion in value from stocks across the medtech sector, according to research by Mizuho.

By Susan Kelly • Nov. 2, 2023

GE HealthCare sales resilient despite ‘highly volatile’ economy

The company raised its earnings forecast for 2023 as it outlined plans to expand margins and navigate China's anti-corruption campaign.

By Elise Reuter • Oct. 31, 2023

4 medtech companies to watch this week in earnings

GE HealthCare and Stryker are among the top medtech companies posting financial results in the third week of this earnings season. 

By Susan Kelly • Oct. 30, 2023

Resmed cuts 5% of staff amid profitability push

The company has stopped some projects that were not working well as it seeks to cut operating costs, CEO Mick Farrell told investors. 

By Elise Reuter • Oct. 30, 2023

Edwards reported double-digit Q3 sales growth, but some analysts are skeptical about 2024

Executives answered questions on the Wednesday earnings call about TAVR’s growth potential and results of a key clinical trial, released earlier this week, comparing the procedure to open-heart surgery.

By Ricky Zipp • Oct. 26, 2023

Boston Scientific looks to new devices in 2024 to drive growth

The company expects to receive FDA approval for its Agent drug-coated balloon and its Farapulse pulsed-field ablation system next year.

By Elise Reuter • Oct. 26, 2023

Thermo Fisher cuts 2023 forecast, citing volatile economic conditions

Customer spending remains constrained overall, while economic conditions in China have weakened, CEO Marc Casper said on a Wednesday earnings call.

By Susan Kelly • Oct. 25, 2023

Danaher Q3 revenue declines as demand challenges continue

Better-than-expected respiratory testing revenue was a bright spot, but the company’s overall orders are “bouncing along” at a bottom, CEO Rainer Blair said on a Tuesday earnings call.

By Susan Kelly • Oct. 24, 2023

Philips’ orders fall in Q3, overshadowing sales growth and return to sleep apnea market

CEO Roy Jakobs said during a third-quarter earnings call that there is still “significant demand” for the company’s sleep apnea products.

By Nick Paul Taylor • Oct. 23, 2023

Intuitive’s Q3 sales miss estimates as robot leasing, China demand weigh

The robotic surgery leader’s overall procedure growth, however, exceeded market expectations.

By Susan Kelly • Oct. 20, 2023

Abbott raises outlook amid strong Q3, sees momentum into 2024

Sales of the FreeStyle Libre continuous glucose monitor rose nearly 31% despite investor worries about the potential impact of weight-loss drugs on demand.

By Susan Kelly • Oct. 18, 2023

J&J to restructure orthopedics business

The company announced the two-year restructuring in its third-quarter earnings call. It expects the changes to accelerate growth and enhance profitability, CFO Joe Wolk said.

By Elise Reuter • Oct. 17, 2023

Bad CRM data can cost your MedTech company 10% in annual revenue

Nearly half of all companies with CRM would say, “it doesn’t live up to the hype.” 

By Clari • Oct. 9, 2023

Artificial heart maker’s cash runway shrinks to 1 month after supply woes hurt sales

France’s Carmat expects revenues of up to 6 million euros in the second half of the year but needs to secure financing to avoid running out of money.

By Nick Paul Taylor • Sept. 28, 2023